Patents Examined by Leigh C. Maier
  • Patent number: 11058697
    Abstract: A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: July 13, 2021
    Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
  • Patent number: 11045485
    Abstract: Compounds, compositions, and methods for the diagnosis and/or treatment of medical conditions involving infections with and colonization by Pseudomonas bacteria including, for example, Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis are described.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: June 29, 2021
    Assignee: GlycoMimetics, Inc.
    Inventors: John L Magnani, Arun K. Sarkar
  • Patent number: 11033566
    Abstract: This invention provides a prophylactic and therapeutic agent for dry eye, having new ingredients to reduce the deterioration of the lacrimal secretory ability and to inhibit the generation of radical oxygen in lacrimal gland tissue. The prophylactic and therapeutic agent for dry eye of this invention contains the maqui berry extract as the active substance of this invention, i.e. containing delphinidin glycoside extracted from the maqui berry and at least one or more of the active substances delphinidin-3-sambubioside-5-glucoside, delphinidin-3,5-diglucoside, delphinidin-3-sambubioside and delphinidin-3-glucoside, preferably delphinidin-3,5-diglucoside.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 15, 2021
    Inventors: Kazuo Tsubota, Shigeru Nakamura, Toshihiro Imada, Junji Tanaka, Takashi Kadekaru, Hiroshi Shimoda, Hiromichi Murai
  • Patent number: 11026965
    Abstract: Disclosed herein are cyclodextrin molecules covalently modified to store and release nitric oxide, as well as methods of making and uses thereof. The covalently modified cyclodextrin molecules may be tailored, in several embodiments, to release nitric oxide in a controlled manner and are useful for reduction and/or eradication of bacteria and for the treatment of disease.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: June 8, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Mark H. Schoenfisch, Haibao Jin
  • Patent number: 11028113
    Abstract: Cyphomycin, an isolated compound of Formula I or IA is provided. A compound isolated from insect Streptomyces and having a chemical formula of C77H122O26 is also provided. Compositions including Cyphomycin, such as pharmaceutical compositions including effective amounts of Cyphomycin for treating fungal infections such as Candida and Aspergillus, including drug-resistant strains thereof, are also disclosed. Methods of treating fungal infections with Cyphomycin and compositions thereof are disclosed.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: June 8, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Timothy S. Bugni, Monica Tallarico Pupo, David R. Andes, Cameron R. Currie, Humberto Enrique Ortega Dominguez
  • Patent number: 10988498
    Abstract: Provided are processes and intermediates for the syntheses of nucleosides of pyrrolo[1,2-f][1,2,4]triazinyl and imidazo[1,2-f][1,2,4]triazinyl heterocycles of Formula I.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: April 27, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas Butler, Aesop Cho, Benjamin R. Graetz, Choung U. Kim, Samuel E. Metobo, Oliver L. Saunders, Andrew W. Waltman, Jie Xu, Lijun Zhang
  • Patent number: 10980828
    Abstract: Described are methods for using cyclodextrin to treat, inhibit, prevent, ameliorate, or cure diabetes or conditions relating to diabetes.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 20, 2021
    Assignee: L & F Research LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10961325
    Abstract: An amphiphilic polymer, an amphiphilic polymer manufacturing method, use of an amphiphilic polymer as a contact lens material, and a contact lens material including the same are provided. The amphiphilic polymer includes amino-conjugated mono-HEMA (mHEMA-NH2) and amphiphilic chitosan bonded to the same. The amphiphilic polymer manufacturing method includes providing a mHEMA-NH2, providing an amphiphilic chitosan, and bonding the mHEMA-NH2 to the amphiphilic chitosan.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: March 30, 2021
    Inventors: Yun-Ru Hsieh, Dean-Mo Liu, Yu-Cheng Jian
  • Patent number: 10953026
    Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: March 23, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Marjan Huizing, William A. Gahl, Irini Manoli, Enriko Klootwijk
  • Patent number: 10933085
    Abstract: The present invention provides compositions comprising hyaluronan with high elasticity, as well as methods for improving joint function, reducing pain associated with joint function and treating osteoarthritis by introducing into a joint a therapeutically effective amount of a composition comprising hyaluronan with high elasticity.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: March 2, 2021
    Assignee: Matrix Biology Institute
    Inventors: Endre A. Balazs, Carlos Belmonte
  • Patent number: 10913945
    Abstract: The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: February 9, 2021
    Inventors: Christian Frauendorf, Mark Cameron
  • Patent number: 10894110
    Abstract: A developable hyaluronic acid microspherical embolic agent includes a hyaluronic acid and an X-ray opaque contrast material; wherein the hyaluronic acid is a modified hyaluronic acid, wherein a modifying method for preparing the modified hyaluronic acid is cross-linking, grafting, esterification, or recombination, and is preferably cross-linking.
    Type: Grant
    Filed: January 27, 2019
    Date of Patent: January 19, 2021
    Assignee: Hangzhou Singclean Medical Products Co., Ltd.
    Inventor: Jianfeng Zhu
  • Patent number: 10889656
    Abstract: The present invention provides a novel sulfated polysaccharide having anticoagulant activity. Specifically, the present invention provides a polysaccharide that includes a repetitive structure of a disaccharide unit composed of a hexuronic acid (HexA) residue and a ?-D-glucosamine (GlcN) residue and having 13% or higher of a 3-O-sulfation rate in GlcN residues.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: January 12, 2021
    Assignee: AJINOMOTO CO., INC.
    Inventors: Kenichi Mori, Yuriko Tokura, Shunsuke Yamazaki, Tomoko Shimizu, Yasuhiro Mihara
  • Patent number: 10882023
    Abstract: A nucleophilic substitution reaction to crosslink cyclodextrin (CD) polymer with rigid aromatic groups, providing a high surface area, mesoporous CD-containing polymers (P-CDPs). The P-CDPs can be used for removing organic contaminants from water. By encapsulating pollutants to form well-defined host-guest complexes with complementary selectivities to activated carbon (AC) sorbents. The P-CDPs can rapidly sequester pharmaceuticals, pesticides, and other organic micropollutants, achieving equilibrium binding capacity in seconds with adsorption rate constants 15-200 times greater than ACs and nonporous CD sorbents. The CD polymer can be regenerated several times, through a room temperature washing procedure, with no loss in performance.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: January 5, 2021
    Assignee: Cornell University
    Inventors: William R. Dichtel, Alaaeddin Alsbaiee, Brian J. Smith, Juan Hinestroza, Diego Alzate-Sanchez, Leilei Xiao, Yuhan Ling, Damian Helbling
  • Patent number: 10869955
    Abstract: The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. The joint may be an arthritic joint, an injured joint or a surgically replaced joint. The therapeutic agent may be an analgesic agent, an anti-inflammatory agent or an immunosuppressive agent. A single administration of the formulation to the joint fat pad delivers a therapeutically effective amount of the therapeutic agent with reduced systemic exposure relative to a single systemic or a single intra-articular administration of a therapeutic dose of an identical therapeutic agent.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: December 22, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Guang-Liang Jiang, Catherine C. Turkel, Michael E. Stern, Christopher S. Schaumberg, Wendy M. Blanda
  • Patent number: 10865255
    Abstract: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: December 15, 2020
    Assignee: Pharmacosmos Holding A/S
    Inventor: Hans Andreasen
  • Patent number: 10857167
    Abstract: Provided herein are compositions and methods related to use of oligosaccharides, such as 2?-fucosyllactose, for increasing weight gain in a subject. In some aspects the compositions and methods are for use in infants, such as premature infants or infants having intestinal failure.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: December 8, 2020
    Inventors: Ardythe L. Morrow, Michael A. Helmrath, Ethan Mezoff
  • Patent number: 10851184
    Abstract: The present invention relates to compositions comprising fractionated alkylated cyclodextrin compositions having a single degree of substitution, and processes for preparing and using the same.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: December 1, 2020
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: Vincent D. Antle, Charles Alan Watson, David W. Miles
  • Patent number: 10842804
    Abstract: Muparfostat for use in reducing intrahepatic tumor recurrence and increasing disease-free survival period in a hepatocellular carcinoma patient with microvascular invasion after curative liver resection, while excluding HCC patients with no vascular invasion and HCC patients with macrovascular invasion, is disclosed. The hepatocellular carcinoma patient with microvascular invasion is identified by examining a resected liver tumor sample from the HCC patient for the presence of microvascular invasion in the sample.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: November 24, 2020
    Assignee: Medigen Biotechnology Corporation
    Inventors: Stanley Chang, Kuan-Lang Lai
  • Patent number: 10842807
    Abstract: The present disclosure provides a method of treating a neurodegenerative disorder, the method comprising administering a DNA methyltransferase inhibitor.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: November 24, 2020
    Assignee: Washington University
    Inventors: Hiroko Yano, Albert Kim